Insmed Reports Positive Phase 3b ENCORE Study Results for ARIKAYCE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Should l Buy INSM?
Source: PRnewswire
Insmed's stock rose by 6.17% as it crossed above the 5-day SMA, reflecting strong investor interest following positive trial results.
The Phase 3b ENCORE study for ARIKAYCE showed significant improvements in respiratory symptom scores and culture conversion rates, with plans for a supplemental NDA filing with the FDA in 2026. This success is expected to enhance market acceptance and drive future growth, attracting investor attention.
The positive results from the trial not only bolster Insmed's position in the market but also indicate potential for label expansion, which could lead to increased sales and further investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INSM
Wall Street analysts forecast INSM stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 153.320
Low
162.00
Averages
219.50
High
263.00
Current: 153.320
Low
162.00
Averages
219.50
High
263.00
About INSM
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Insmed Shares Rise 5.5% Following Positive Competitive Data
- Stock Price Surge: Insmed shares rallied 5.5% to close at $153.32 in the last trading session, with notable trading volume indicating strong market optimism regarding the company's future potential.
- Impact of Competitive Data: This price increase is linked to positive late-stage study results from rival United Therapeutics, which demonstrated that Tyvaso improved forced vital capacity (FVC) by 130.1 mL in idiopathic pulmonary fibrosis patients, indirectly validating the therapeutic potential of treprostinil.
- Product Development Progress: Insmed's TPIP, a prodrug of treprostinil designed for once-daily dosing, is on track to begin a late-stage study in IPF in the second half of 2026, which could significantly enhance its competitive position in the market.
- Financial Expectations: Insmed anticipates a quarterly loss of $1.00 per share, reflecting a year-over-year increase of 29.6%, while revenues are expected to reach $299.57 million, up 222.7%, indicating strong momentum in revenue growth.
See More
Mixed Close for US Stocks as Nasdaq Hits 7.75-Month Low Amid Middle East Tensions
- Divergent Market Performance: On Monday, the S&P 500 index fell by 0.39%, while the Nasdaq 100 hit a 7.75-month low, indicating market concerns over the Middle East situation, particularly exacerbated by a sell-off in chip stocks, which negatively impacted investor confidence.
- Declining Bond Yields: The 10-year T-note yield dropped by 8 basis points to 4.34%, reflecting market fears that the ongoing war in the Middle East could lead to fuel shortages, potentially suppressing expectations for Fed rate hikes and highlighting economic growth uncertainties.
- Rising Crude Oil Prices: Crude oil prices surged over 3% to a three-week high due to Iranian attacks on the Strait of Hormuz, indicating severe threats to global energy supply chains, which could lead to soaring prices in the future and impact the global economy.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity survey fell to -0.2, below the expected 2.0, reflecting signs of economic slowdown that could influence corporate investment decisions and future economic growth.
See More
US Stock Market Declines Amid Rising Oil Prices
- Oil Price Surge Impacts Markets: The S&P 500 Index fell by 0.75%, the Dow Jones Industrial Average by 0.21%, and the Nasdaq 100 by 1.18% as the market reacts to the first oil settlement exceeding $100 since 2022, highlighting concerns over rising energy costs amid ongoing supply chain risks.
- Uncertain Fed Policy Outlook: Federal Reserve Chair Jerome Powell noted that while the central bank is monitoring the surge in energy prices, its tools to address supply-side shocks are limited, with markets pricing in only a 3% chance of a 25 bp rate hike at the April meeting, indicating investor uncertainty about future monetary policy.
- Escalating Middle East Tensions: US and Israeli forces continue military operations in Iran, with the Pentagon preparing for weeks of ground operations as approximately 3,500 sailors and Marines arrive in the region, potentially exacerbating global energy supply issues.
- Positive Bond Market Reaction: The 10-year Treasury yield fell to 4.330% as speculation grows that the ongoing conflict in the Middle East may lead to fuel shortages, offsetting inflation fears and supporting Treasury prices amid declining inflation expectations.
See More
Mixed U.S. Stock Indices Amid Rising Oil Prices
- Mixed Stock Performance: The S&P 500 Index fell by 0.29%, while the Dow Jones Industrial Average rose by 0.26%, and the Nasdaq 100 Index decreased by 0.67%, indicating a complex market reaction to Federal Reserve policies and international tensions.
- Rising Oil Prices: Crude oil prices surged over 2% to a three-week high due to disruptions in oil and gas flows through the Strait of Hormuz caused by the Iran conflict, which could negatively impact global economic growth.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity index dropped from -0.4 to -0.2, falling short of the expected increase to 2.0, suggesting challenges in economic recovery that may influence future policy decisions.
- Escalating International Tensions: U.S. and Israeli military actions against Iran have intensified, with 3,500 sailors and Marines deployed to the Middle East, potentially leading to further volatility in energy markets and impacting global supply chains.
See More
US Stocks Rise as Oil Prices Hit Three-Week High
- Market Gains: The S&P 500 Index rose by 0.58%, the Dow Jones Industrial Average increased by 0.91%, and the Nasdaq 100 Index climbed by 0.30%, reflecting a positive market sentiment amid expectations that the Fed may keep interest rates unchanged.
- Declining Bond Yields: The 10-year Treasury note yield fell by 10 basis points to 4.33%, driven by concerns that the ongoing war in the Middle East could lead to a fuel shortage, potentially hindering global economic growth and influencing the Fed's future rate decisions.
- Rising Oil Prices: Crude oil prices surged over 2% to a three-week high due to Iranian attacks on shipping, raising fears that the closure of the Strait of Hormuz could disrupt global oil and gas supplies, which may lead to significant price increases.
- Manufacturing Activity Decline: The Dallas Fed's manufacturing activity survey dropped by 0.4 to -0.2, falling short of the expected increase to 2.0, indicating signs of economic slowdown that could impact future investment decisions.
See More
Middle East Tensions Impact Global Markets
- Market Recovery: The S&P 500 Index rose by 0.42%, the Dow Jones Industrial Average increased by 0.64%, and the Nasdaq 100 Index gained 0.32%, indicating a short-term market rebound amid escalating tensions in the Middle East, as investor confidence in future economic growth shows signs of recovery.
- Declining Bond Yields: The 10-year T-note yield fell by 8 basis points to 4.35%, reflecting market concerns that the ongoing war in the Middle East may lead to fuel shortages, thereby suppressing inflation expectations and potentially keeping the Fed from raising interest rates in upcoming meetings.
- Rising Oil Prices: Crude oil prices surged over 1% to a three-week high due to Iranian attacks on shipping, with fears that the closure of the Strait of Hormuz could disrupt global oil supplies, potentially driving prices to exceed the 2008 record high.
- Energy Infrastructure Damage: The International Energy Agency reported that more than 40 energy sites across nine Middle Eastern countries have been severely damaged, which could prolong disruptions to global supply chains after the war ends, further impacting international market stability.
See More
Insmed Shares Rise 5.5% Following Positive Competitive Data
- Stock Price Surge: Insmed shares rallied 5.5% to close at $153.32 in the last trading session, with notable trading volume indicating strong market optimism regarding the company's future potential.
- Impact of Competitive Data: This price increase is linked to positive late-stage study results from rival United Therapeutics, which demonstrated that Tyvaso improved forced vital capacity (FVC) by 130.1 mL in idiopathic pulmonary fibrosis patients, indirectly validating the therapeutic potential of treprostinil.
- Product Development Progress: Insmed's TPIP, a prodrug of treprostinil designed for once-daily dosing, is on track to begin a late-stage study in IPF in the second half of 2026, which could significantly enhance its competitive position in the market.
- Financial Expectations: Insmed anticipates a quarterly loss of $1.00 per share, reflecting a year-over-year increase of 29.6%, while revenues are expected to reach $299.57 million, up 222.7%, indicating strong momentum in revenue growth.
See More
Mixed Close for US Stocks as Nasdaq Hits 7.75-Month Low Amid Middle East Tensions
- Divergent Market Performance: On Monday, the S&P 500 index fell by 0.39%, while the Nasdaq 100 hit a 7.75-month low, indicating market concerns over the Middle East situation, particularly exacerbated by a sell-off in chip stocks, which negatively impacted investor confidence.
- Declining Bond Yields: The 10-year T-note yield dropped by 8 basis points to 4.34%, reflecting market fears that the ongoing war in the Middle East could lead to fuel shortages, potentially suppressing expectations for Fed rate hikes and highlighting economic growth uncertainties.
- Rising Crude Oil Prices: Crude oil prices surged over 3% to a three-week high due to Iranian attacks on the Strait of Hormuz, indicating severe threats to global energy supply chains, which could lead to soaring prices in the future and impact the global economy.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity survey fell to -0.2, below the expected 2.0, reflecting signs of economic slowdown that could influence corporate investment decisions and future economic growth.
See More
US Stock Market Declines Amid Rising Oil Prices
- Oil Price Surge Impacts Markets: The S&P 500 Index fell by 0.75%, the Dow Jones Industrial Average by 0.21%, and the Nasdaq 100 by 1.18% as the market reacts to the first oil settlement exceeding $100 since 2022, highlighting concerns over rising energy costs amid ongoing supply chain risks.
- Uncertain Fed Policy Outlook: Federal Reserve Chair Jerome Powell noted that while the central bank is monitoring the surge in energy prices, its tools to address supply-side shocks are limited, with markets pricing in only a 3% chance of a 25 bp rate hike at the April meeting, indicating investor uncertainty about future monetary policy.
- Escalating Middle East Tensions: US and Israeli forces continue military operations in Iran, with the Pentagon preparing for weeks of ground operations as approximately 3,500 sailors and Marines arrive in the region, potentially exacerbating global energy supply issues.
- Positive Bond Market Reaction: The 10-year Treasury yield fell to 4.330% as speculation grows that the ongoing conflict in the Middle East may lead to fuel shortages, offsetting inflation fears and supporting Treasury prices amid declining inflation expectations.
See More
Mixed U.S. Stock Indices Amid Rising Oil Prices
- Mixed Stock Performance: The S&P 500 Index fell by 0.29%, while the Dow Jones Industrial Average rose by 0.26%, and the Nasdaq 100 Index decreased by 0.67%, indicating a complex market reaction to Federal Reserve policies and international tensions.
- Rising Oil Prices: Crude oil prices surged over 2% to a three-week high due to disruptions in oil and gas flows through the Strait of Hormuz caused by the Iran conflict, which could negatively impact global economic growth.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity index dropped from -0.4 to -0.2, falling short of the expected increase to 2.0, suggesting challenges in economic recovery that may influence future policy decisions.
- Escalating International Tensions: U.S. and Israeli military actions against Iran have intensified, with 3,500 sailors and Marines deployed to the Middle East, potentially leading to further volatility in energy markets and impacting global supply chains.
See More
US Stocks Rise as Oil Prices Hit Three-Week High
- Market Gains: The S&P 500 Index rose by 0.58%, the Dow Jones Industrial Average increased by 0.91%, and the Nasdaq 100 Index climbed by 0.30%, reflecting a positive market sentiment amid expectations that the Fed may keep interest rates unchanged.
- Declining Bond Yields: The 10-year Treasury note yield fell by 10 basis points to 4.33%, driven by concerns that the ongoing war in the Middle East could lead to a fuel shortage, potentially hindering global economic growth and influencing the Fed's future rate decisions.
- Rising Oil Prices: Crude oil prices surged over 2% to a three-week high due to Iranian attacks on shipping, raising fears that the closure of the Strait of Hormuz could disrupt global oil and gas supplies, which may lead to significant price increases.
- Manufacturing Activity Decline: The Dallas Fed's manufacturing activity survey dropped by 0.4 to -0.2, falling short of the expected increase to 2.0, indicating signs of economic slowdown that could impact future investment decisions.
See More
Middle East Tensions Impact Global Markets
- Market Recovery: The S&P 500 Index rose by 0.42%, the Dow Jones Industrial Average increased by 0.64%, and the Nasdaq 100 Index gained 0.32%, indicating a short-term market rebound amid escalating tensions in the Middle East, as investor confidence in future economic growth shows signs of recovery.
- Declining Bond Yields: The 10-year T-note yield fell by 8 basis points to 4.35%, reflecting market concerns that the ongoing war in the Middle East may lead to fuel shortages, thereby suppressing inflation expectations and potentially keeping the Fed from raising interest rates in upcoming meetings.
- Rising Oil Prices: Crude oil prices surged over 1% to a three-week high due to Iranian attacks on shipping, with fears that the closure of the Strait of Hormuz could disrupt global oil supplies, potentially driving prices to exceed the 2008 record high.
- Energy Infrastructure Damage: The International Energy Agency reported that more than 40 energy sites across nine Middle Eastern countries have been severely damaged, which could prolong disruptions to global supply chains after the war ends, further impacting international market stability.
See More
